Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

01 January 2008

Pharmacokinetic principles of immunosuppressive-drugs

K. Budde, P. Glander

Ann Transplant 2008; 13(1): 12-12 :: ID: 880167

Abstract

The combination of synergistic drugs is the main strategy to prevent early acute rejection and to provide long-term effective rejection prophylaxis. Evaluation of drug concentrations to guide drug dosing is routinely established for CNIs and mTOR inhibitors. Arguments in favour of TDM are the large inter-patient variability of many immunosuppressants with their potential for severe toxicity and drug-to-drug interactions. The manuscript discusses several confounding factors, which influence the appropriate therapeutic window. These include decreasing risk of rejection over time, cumulative risk for toxicity with time, and the synergistic potential of combination immunosuppressive therapy with respect to efficacy and shared toxicities. In addition, a long list of donor and recipient characteristics have a direct or indirect effect on the therapeutic window, but have not been evaluated in rigorous, prospective trials. Unfortunately, only a very small number of adequately powered, prospective randomized trials evaluate different therapeutic windows for immunosuppressants or even the utility of therapeutic drug monitoring at all. Other problems of TDM include the inherent variability of absorption and drug levels and a suboptimal correlation between pharmacokinetic surrogate parameters and drug exposure for most drugs. Drugs with a high intra-patient day-to-day variability may be less suited for TDM compared to drugs with a high inter-patient, but low intra-patient variability. Furthermore it is not known whether the same parameter is suitable for controlling efficacy as well toxicity. With cumulative overexposure the effect of time might be more far more important than a specific level at a given time point and provides another fundamental dimension. A new approach of TDM, classified as pharmacodynamic (PD) drug monitoring, which directly reflects the drug's biological effects has been proposed to better assess the individual state of immunosuppression, however difficult test systems and lack of prospective trials limit this approach currently. Future studies have to take these considerations into account in order to better guide immunosuppression towards a more individualized therapy, which remains an important goal in transplant medicine.

Keywords: immunosuppressive therapy, Drug Monitoring, cancer, carcinomatosis, raltitrexed

Add Comment 0 Comments

In Press

07 Mar 2024 : Original article  

Outcomes of Renal Transplantation in ANCA-Associated Vasculitis

Ann Transplant In Press; DOI: 10.12659/AOT.943433  

08 Mar 2024 : Original article  

Association of Coronary Calcium Score on Cardiac PET During Pre-Kidney Transplant Assessment with Persisten...

Ann Transplant In Press; DOI: 10.12659/AOT.943532  

14 Mar 2024 : Original article  

Impact of Blood Products Transfusion on Patients in the Immediate Post-Lung Transplant Period: A Cohort Study

Ann Transplant In Press; DOI: 10.12659/AOT.943652  

14 Mar 2024 : Case report  

Treatment of Cavernous Transformation of Portal Vein Caused by Hepatic Cystic Echinococcosis Using Ex Vivo ...

Ann Transplant In Press; DOI: 10.12659/AOT.942358  

Most Viewed Current Articles

05 Apr 2022 : Original article  

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

12 Jan 2022 : Original article  

Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...

DOI :10.12659/AOT.934738

Ann Transplant 2022; 27:e934738

22 Nov 2022 : Original article  

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

15 Mar 2022 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358